According to the latest data from the Hong Kong Stock Exchange, on September 23, shareholders of UNI-BIO GROUP (00690) deposited shares into HSBC with a market value of HK$113 million, representing 12.33% of the company's shares.
Recently, UNI-BIO GROUP announced that its wholly-owned subsidiary Beijing Bokang Jiankang Gene Technology Co., Ltd. has signed a strategic cooperation agreement with Sinovac Biotech Co., Ltd. Under this agreement, Sinovac has been granted exclusive commercial rights to market the group's innovative osteoporosis treatment drug Bogutai® in six countries within the cooperation region: Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.